Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light-Activated therapy targets pancreatic tumors during surgery

NCT ID NCT07698613

Not yet recruiting Disease control Sponsor: Brown University Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests a new approach called photoimmunotherapy for people with locally advanced or borderline resectable pancreatic cancer. Patients receive an injection of ASP-1929, a drug that attaches to cancer cells and becomes active when exposed to a specific light. During surgery, if the tumor cannot be removed, a laser activates the drug to destroy cancer cells. The trial aims to see if this treatment is safe and helps prevent the cancer from growing for at least six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ASP-1929 (cetuximab sarotalocan) photoimmunotherapy
What this could lead to
If successful, this approach could offer a new treatment option for patients with locally advanced pancreatic cancer that cannot be surgically removed, potentially improving survival.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. The treatment requires surgery and carries risks of side effects from the drug and laser activation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER BORDERLINE PANCREATIC CANCER PATIENTS DIAGNOSED WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER NOT AMENABLE TO CURATIVE SURGICAL RESECTION PANCREATIC CANCER RESECTABLE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Rhode Island and the Miriam Hospitals (Brown University Health)

    Providence, Rhode Island, 02903/02906, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.